Clinical Trials in Central/Eastern Europe: Industry Viewpoint

Abstract

Over the past 15 years pharmaceutical companies and contract research organizations (CROs) have increased their presence in Central and Eastern Europe, and taken increasing advantage of the opportunities for conducting clinical trials there. Data from studies in these countries have been submitted by several Western European and American companies for marketing approval over the past five years and accepted by Western regulatory agencies and the Food and Drug Administration. Access to rare populations and a high prevalence of certain disorders puts countries of Central and Eastern Europe high on the priority list for clinical trials in some therapeutic areas. Additional numbers of patients are an asset where large populations are needed in multicenter Phase HI studies. As enrollment is fast and compliance high, considerable time savings are achieved. There are, however, differences between running clinical trials in Western and Central/Eastern Europe and these will be considered.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Hughes G. Contract clinical research in Central and Eastern Europe. App Clin Trials. 1994;3(6):52–59.

    Google Scholar 

  2. 2.

    Ward P. Conducting trials in Eastern Europe. App Clin Trials. 1995:45–48.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. Benona Lillian Natorff MD, MFPM.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Natorff, B.L. Clinical Trials in Central/Eastern Europe: Industry Viewpoint. Ther Innov Regul Sci 32, 129–133 (1998). https://doi.org/10.1177/009286159803200117

Download citation

Key Words

  • Clinical trials
  • Central/Eastern Europe